Theralase Technologies Inc. V.TLT

New Study of TLD1433 & TLD1633 by Dr. McFarland et al.

[Eoganacht]

McFarland Labs and the Leibniz Insitute of Photonic Technology in Germany collaborated on this study to determine the mechanism behind the photoinduced cytotoxicity of TLD1433 and its derivative TLD1633. Only the abstract is available for free. The full text of this one costs US $40.

Interaction with a Biomolecule Facilitates the Formation of the Function-Determining Long-Lived Triplet State in a Ruthenium Complex for Photodynamic Therapy

Avinash Chettri, Houston D. Cole, John A. Roque III, Kilian R. A. Schneider, Tingxiang Yang, Colin G. Cameron, Sherri A. McFarland, and Benjamin Dietzek-Ivani

Publication Date: February 18, 2022

Abstract

 

TLD1433 is the first ruthenium (Ru)-based photodynamic therapy (PDT) agent to advance to clinical trials and is currently in a phase II study for treating nonmuscle bladder cancer with PDT. Herein, we present a photophysical study of TLD1433 and its derivative TLD1633 using complex, biologically relevant solvents to elucidate the excited-state properties that are key for biological activity. The complexes incorporate an imidazo [4,5-f][1,10]phenanthroline (IP) ligand appended to α-ter- or quaterthiophene, respectively, where TLD1433 = [Ru(4,4′-dmb)2(IP-3T)]Cl2 and TLD1633 = [Ru(4,4′-dmb)2(IP-4T)]Cl2 (4,4′-dmb = 4,4′-dimethyl-2,2′-bipyridine; 3T = α-terthiophene; 4T = α-quaterthiophene). Time-resolved transient absorption experiments demonstrate that the excited-state dynamics of the complexes change upon interaction with biological macromolecules (e.g., DNA). In this case, the accessibility of the lowest-energy triplet intraligand charge-transfer (3ILCT) state (T1) is increased at the expense of a higher-lying 3ILCT state. We attribute this behavior to the increased rigidity of the ligand framework upon binding to DNA, which prolongs the lifetime of the T1 state. This lowest-lying state is primarily responsible for O2 sensitization and hence photoinduced cytotoxicity. Therefore, to gain a realistic picture of the excited-state kinetics that underlie the photoinduced function of the complexes, it is necessary to interrogate their photophysical dynamics in the presence of biological targets once they are known.

[Tapps21]

Another amazing find Eog!!  At any time, with the worldwide patents Tlt has, a company could step in and fund(if not buy out) Theralase and really show the rest of the world the truly amazing impact this could have on humanity! Thanks as always 

[jicoop]

FINALLY! Some luv for TLD 1633 , still in the picture, now wondering whatever happened to the other compound they had in their arsenal that was even a billion times more powerful than these two, I will try to look back on the older news releases and find the exact wording. Coop ============================================

[Eoganacht]

Hi Coop - I had forgotten about TLD1633. Back n 2017 they told us it was 15% more effective against gbm than TLD1433 and had a higher safety profile. Toronto, Ontario – September 12, 2017   Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the

[Infinity]

Great info from Coop and insight from Eoga.. I can feel the excitement building up towards some long awaited news regarding BTD from FDA for TLT's TLD 1433...  The next News release is around the corner and could very well be the Pivot point for TLT.  

[99942Apophis]

Infinity wrote Great info from Coop and insight from Eoga.. I can feel the excitement building up towards some long awaited news regarding BTD from FDA for TLT's TLD 1433...  The next News release is around the corner and could very well be the Pivot point for TLT.   Nicely said Infinity, yes we all feel that excitement too.